METHODS	Six hundred forty-nine patients with previously untreated mRCC were randomly assigned to receive bevacizumab ( 10 mg/kg every 2 weeks ) plus IFN ( 9 MIU subcutaneously three times a week ; n = 327 ) or IFN plus placebo ( n = 322 ) in a multicenter , randomized , double-blind , phase III trial .\